

GASTROENTEROLOGY

PAPER-III

Time: 3 hours
Max. Marks:100

GASTRO/J/19/10/III

Important Instructions:

- Attempt all questions in order.
- Each question carries 10 marks.
- Read the question carefully and answer to the point neatly and legibly.
- Do not leave any blank pages between two answers.
- Indicate the question number correctly for the answer in the margin space.
- Answer all the parts of a single question together.
- Start the answer to a question on a fresh page or leave adequate space between two answers.
- Draw table/diagrams/flowcharts wherever appropriate

Write short notes on:

- a) Newer therapies for Chronic Hepatitis C. 3+3+2+2
 - b) Treatment of Chronic Hepatitis C in chronic kidney diseases.
 - c) Immune escape phenomenon in Hepatitis C infection.
 - d) Drug resistance in Chronic Hepatitis C.
- a) POEM Vs Pneumatic Dilatation in Achalasia Cardia. 4+3+3
 - b) Endoscopic Vs Surgical drainage in Walled off Necrosis.
 - c) Endoscopic Vs Surgical treatment of Barrett's Esophagus.
- a) Role of simulators in training and teaching in GI Endoscopy. 4+3+3
 - b) Confocal Endoscopy.
 - c) Narrow Band Imaging.
- a) Gut microbiota in inflammatory bowel disease (IBD). 3+4+3
 - b) Fecal microbiota transplant in liver diseases.
 - c) GLP-1 therapy in IBD.
- a) Approach to a case of cystic lesions of pancreas. 5+5
 - b) Role of EUS in diagnosis and treatment of pancreatic diseases.
- a) Newer drugs in pipeline for treatment of Chronic Hepatitis B. 5+5
 - b) Status of vaccine for Hepatitis E.
- a) Enteric duplication cysts. 5+5
 - b) Abdominal cocoon.

P.T.O.

GASTROENTEROLOGY

PAPER-III

- | | | |
|-----|--|-------|
| 8. | a) Role of intestinal and epithelial TLR5 in metabolic syndrome.
b) Genomic profiling in targeted therapy in biliary cancers.
c) Role of proteases in GI diseases. | 4+3+3 |
| 9. | a) Role of EUS in management of biliary tract diseases.
b) Applications of radiofrequency ablation in GI cancers. | 5+5 |
| 10. | a) Hepatic regeneration and its clinical implications.
b) Biological markers for liver fibrosis.
c) Biosimilars in IBD. | 4+3+3 |
